CN114920782B - 一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 - Google Patents
一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114920782B CN114920782B CN202210591572.6A CN202210591572A CN114920782B CN 114920782 B CN114920782 B CN 114920782B CN 202210591572 A CN202210591572 A CN 202210591572A CN 114920782 B CN114920782 B CN 114920782B
- Authority
- CN
- China
- Prior art keywords
- formula
- complex
- compound
- negative
- ruthenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229910052707 ruthenium Inorganic materials 0.000 title claims abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000003446 ligand Substances 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 229910052786 argon Inorganic materials 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- 125000004424 polypyridyl Polymers 0.000 claims description 3
- 235000010333 potassium nitrate Nutrition 0.000 claims description 3
- 239000004323 potassium nitrate Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 22
- 241000894006 Bacteria Species 0.000 abstract description 11
- 150000004696 coordination complex Chemical class 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 206010059866 Drug resistance Diseases 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 210000000170 cell membrane Anatomy 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 229940079593 drug Drugs 0.000 description 22
- 241000701806 Human papillomavirus Species 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 11
- 241000341655 Human papillomavirus type 16 Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003303 ruthenium Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KCALAFIVPCAXJI-UHFFFAOYSA-N 1,10-phenanthroline-5,6-dione Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CN=C3C2=N1 KCALAFIVPCAXJI-UHFFFAOYSA-N 0.000 description 1
- NSDOEOWTTXZPFG-UHFFFAOYSA-N 4-(4-bromobutoxy)benzaldehyde Chemical compound BrCCCCOC1=CC=C(C=O)C=C1 NSDOEOWTTXZPFG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210591572.6A CN114920782B (zh) | 2022-05-28 | 2022-05-28 | 一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210591572.6A CN114920782B (zh) | 2022-05-28 | 2022-05-28 | 一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114920782A CN114920782A (zh) | 2022-08-19 |
CN114920782B true CN114920782B (zh) | 2023-12-19 |
Family
ID=82811600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210591572.6A Active CN114920782B (zh) | 2022-05-28 | 2022-05-28 | 一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114920782B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108358972A (zh) * | 2018-02-01 | 2018-08-03 | 大连理工大学 | 邻菲罗啉钌配合物类光敏染料及其制备方法和用途 |
CN113072611A (zh) * | 2021-04-06 | 2021-07-06 | 江西科技师范大学 | 一种甘草次酸修饰的多吡啶钌配合物及其制备方法和应用 |
CN113336797A (zh) * | 2021-04-06 | 2021-09-03 | 江西科技师范大学 | 一种具有三苯基膦结构的钌多吡啶配合物及其制备方法和应用 |
-
2022
- 2022-05-28 CN CN202210591572.6A patent/CN114920782B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108358972A (zh) * | 2018-02-01 | 2018-08-03 | 大连理工大学 | 邻菲罗啉钌配合物类光敏染料及其制备方法和用途 |
CN113072611A (zh) * | 2021-04-06 | 2021-07-06 | 江西科技师范大学 | 一种甘草次酸修饰的多吡啶钌配合物及其制备方法和应用 |
CN113336797A (zh) * | 2021-04-06 | 2021-09-03 | 江西科技师范大学 | 一种具有三苯基膦结构的钌多吡啶配合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114920782A (zh) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113072611B (zh) | 一种甘草次酸修饰的多吡啶钌配合物抗菌剂的制备方法 | |
CN113336797B (zh) | 一种具有三苯基膦结构的钌多吡啶配合物及其制备方法和应用 | |
CN112409310B (zh) | 一种具有lsd1抑制活性的化合物、制备方法及应用 | |
CN111808091B (zh) | 一种二醇二氮烯鎓席夫碱铜配合物、制备方法及生物活性 | |
CN111349050B (zh) | 三唑类cyp51-hdac双靶点抗真菌化合物及其制备方法与应用 | |
CN110128382B (zh) | 一种水黄皮籽素的制备方法和应用 | |
CN114920782B (zh) | 一种具有hpv阳转阴及抑菌功能的钌多吡啶配合物及其制备方法和应用 | |
CN100387596C (zh) | 13-己基小檗碱盐的制备及其抗病毒和抗菌作用 | |
CN109223741A (zh) | 一种金刚乙胺席夫碱的用途 | |
CN113121370A (zh) | 十六烷氨丁三醇化合物、合成方法及其在抗肿瘤、抗真菌方面的应用 | |
CN110759866B (zh) | 一类甲硝唑接丙谷二肽化合物及其制备与应用 | |
CN111072722B (zh) | 安德森多酸及其作为cvb3病毒抑制剂的应用 | |
CN110368380B (zh) | 异黄酮类化合物Final-2在制备肺癌细胞葡萄糖转运蛋白表达抑制剂中的应用 | |
CN115872948A (zh) | 一种利可君的晶型b及其制备方法、用途 | |
CN107746423B (zh) | 麦角甾-7,22-二烯-3-酮肟及其制备方法和在制备抗菌药物中的应用 | |
CN114751942B (zh) | 一种具有三乙胺结构的钌多吡啶配合物及其制备方法和应用 | |
CN113413386B (zh) | 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 | |
CN117695290B (zh) | 一种具有烷基链修饰的铜配合物的制备方法和应用 | |
CN115819488B (zh) | 一种24,31-氢化茯苓酸、制备方法及其应用 | |
CN108440427B (zh) | 一种锌氟康唑十钒酸盐化合物及应用 | |
CN113292532B (zh) | 一种多取代萘醌衍生物及其制备方法与应用 | |
CN113045498B (zh) | 一种1,5-二芳基吡唑衍生物、合成方法及用途 | |
CN107007604B (zh) | 一种哌啶-溴酚-吲哚酮杂合体化合物在抗肿瘤药物中的应用 | |
CN115286574B (zh) | Blvrb酶功能抑制剂及其制备方法和用途 | |
CN108774161B (zh) | 六种parp1抑制剂的制备及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 118, Building B, Science and Technology Innovation Space, Hongjiaozhou Campus, Jiangxi Normal University, No. 589 Xuefu Avenue, Honggutan District, Nanchang City, Jiangxi Province, 330000 Patentee after: Nanchang Youduo Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: Room 111-14, Unit 1, Building 1, Xinghai Haoting, No. 666 Xinghai Hubei Road, Xinqi Zhou, Ganjiang New Area, Nanchang City, Jiangxi Province, 330000 Patentee before: Jiangxi Ganjiang New District Youduo Pharmaceutical Technology Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: No. 208, Building 1, No. 92 Shennong West Avenue, Traditional Chinese Medicine Innovation City, Ganjiang New District, Nanchang City, Jiangxi Province, 330000 Patentee after: Jiangxi Senteng Biopharmaceutical Co.,Ltd. Country or region after: China Address before: Room 118, Building B, Science and Technology Innovation Space, Hongjiaozhou Campus, Jiangxi Normal University, No. 589 Xuefu Avenue, Honggutan District, Nanchang City, Jiangxi Province, 330000 Patentee before: Nanchang Youduo Pharmaceutical Technology Co.,Ltd. Country or region before: China |